UNSPSC 51294513: Paroxetine hydrochloride

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 41VRH5220H. European Medicines Agency schedules Paroxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09631MIG. Paroxetine generally arises in the molecular formula C19H20FNO3.

UNSPSC 51294513 Paroxetine hydrochloride is a Commodity code that nominally covers a specific antidepressant pharmaceutical ingredient, but recent state and local procurement activity under this code does not align with single-molecule pharmaceutical procurement. Instead, the opportunities posted under this code reflect broader pharmaceutical procurement and public health supply initiatives spanning naloxone, over-the-counter products, generic pharmaceuticals, and direct-to-manufacturer prescription programs. State and local issuing bodies—including counties, state health and human services departments, and multistate cooperative purchasing alliances—are using this code to solicit supply agreements for pharmaceutical products and drug-distribution systems that serve community health, emergency response, and government employee benefit programs rather than purchasing paroxetine hydrochloride specifically. The code shows activity from county health departments, state HHS commissions, and cooperative purchasing organizations that aggregate demand across multiple jurisdictions.

Recent opportunities span Florida, Texas, Minnesota, and Oregon. Seminole County, Florida posted IFB 60459723LAS (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with electronic bidding required and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026, response due April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health, Morris & Dickson) and comply with cGMP and DSCSA certifications, with award weighting heavily favoring price competitiveness (75 percent) and contract effectiveness July 1, 2026.